These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36640730)

  • 1. Who has poor insight, my patient suffering from schizophrenia or myself?
    Davidson M; Agid O
    Eur Neuropsychopharmacol; 2023 Mar; 68():27-29. PubMed ID: 36640730
    [No Abstract]   [Full Text] [Related]  

  • 2. Why do patients with schizophrenia who have poor insight still take antipsychotics? Memory deficits as moderators between adherence belief and behavior.
    Staring AB; van der Gaag M; Duivenvoorden HJ; Weiden PJ; Mulder CL
    J Psychiatr Pract; 2011 Sep; 17(5):320-9. PubMed ID: 21926527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 1997 Sep; 58(9):381-2. PubMed ID: 9378687
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential lower efficacy of molindone among first-generation antipsychotics.
    Waugaman RM
    Am J Psychiatry; 2009 Apr; 166(4):491; author reply 492-3. PubMed ID: 19339370
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.
    Wehring HJ; Heishman SJ; McMahon RP; Liu F; Feldman S; Raley H; Weiner E; Kelly DL
    J Dual Diagn; 2017; 13(1):36-42. PubMed ID: 28166471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.
    Purdon SE
    J Psychiatry Neurosci; 2000 Mar; 25(2):108-16. PubMed ID: 10740984
    [No Abstract]   [Full Text] [Related]  

  • 8. What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?
    Kane JM
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S3-6. PubMed ID: 9218161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Revealed" Depression and drug treatment for schizophrenia.
    Knights A; Hirsch SR
    Arch Gen Psychiatry; 1981 Jul; 38(7):806-11. PubMed ID: 6113822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early detection and treatment of schizophrenia].
    Hasan A; Falkai P; Wobrock T
    MMW Fortschr Med; 2010 Mar; 152(9):53-5. PubMed ID: 20384099
    [No Abstract]   [Full Text] [Related]  

  • 11. Lilliputian hallucinations in schizophrenia: a case report.
    Grover S; Kattharaghatta Girigowda V; Kumar V
    Afr J Psychiatry (Johannesbg); 2012 Sep; 15(5):311, 313. PubMed ID: 23044883
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel antipsychotics and the neuropsychological deficiencies of schizophrenia.
    Hawkins KA
    J Psychiatry Neurosci; 2000 Mar; 25(2):105-7. PubMed ID: 10740983
    [No Abstract]   [Full Text] [Related]  

  • 13. [Gilbert's syndrome and schizophrenia].
    Molina Ramos R; Villanueva Curto S; Molina Ramos JM
    Actas Esp Psiquiatr; 2006; 34(3):206-8. PubMed ID: 16736395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of simple schizophrenia with atypical neuroleptics (clozapine, risperidol)].
    Rollnik JD; Schneider U; Emrich HM
    Nervenarzt; 2001 May; 72(5):380-3. PubMed ID: 11386150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influences of second generation antipsychotics on the course of schizophrenia].
    Messer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S161-3. PubMed ID: 15570540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
    Kim J; Ozzoude M; Nakajima S; Shah P; Caravaggio F; Iwata Y; De Luca V; Graff-Guerrero A; Gerretsen P
    Neuropharmacology; 2020 May; 168():107634. PubMed ID: 31077729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
    Rahiminejad F; Akhondzadeh S
    Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report.
    Kane JM; Dauphinais D; Barnes TR; Adler LA; Rifkin A
    Psychopharmacol Bull; 1993; 29(1):45-9. PubMed ID: 8104351
    [No Abstract]   [Full Text] [Related]  

  • 20. Another view of therapy for cognition in schizophrenia.
    Carpenter WT; Gold JM
    Biol Psychiatry; 2002 Jun; 51(12):969-71. PubMed ID: 12062880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.